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SummAry
Despite an abundance of long-term pharmacological treatments for recurrent vertigo attacks due to ménière’s disease, there is no general 
agreement on the their efficacy. We present the results of a retrospective study based on a 10-year experience with two long-term medical 
protocols prescribed to patients affected by ménière’s disease (diagnosed according to the American Academy of otolaryngology-head 
and neck Surgery Committee on hearing and Equilibrium guidelines) who completed treatments in the period 1999-2009. A total of 113 
medical records were analysed; 53 patients received betahistine-dihydrochloride at on-label dosage (32 mg die) for six months, and 60 
patients were treated with the same regimen and nimodipine (40 mg die) as an add-therapy during the same period. nimodipine, a 1,4-di-
hydropyridine that selectively blocks l-type voltage-sensitive calcium channels, has previously been tested as a monotherapy for recurrent 
vertigo of labyrinthine origin in a multinational, double-blind study with positive results. A moderate reduction of the impact of vertigo on 
quality of life (as assessed by the Dizziness handicap inventory) was obtained in patients after therapy with betahistine (p < 0.05), but a 
more significant effect was achieved in patients treated by combined therapy (p < 0.005). in the latter group, better control of vertigo was 
seen with a greater reduction of frequency of attacks (p < 0.005). Both protocols resulted in a significant improvement of static postural 
control, although a larger effect on body sway area in all tests was obtained by the fixed combination of drugs. in contrast, no beneficial 
effect on either tinnitus annoyance (as assessed by the Tinnitus handicap inventory) and hearing loss (pure-tone average at 0.5, 1, 2, 3 khz 
frequencies of the affected ear) was recorded in patients treated with betahistine as monotherapy (p > 0.05), whereas the fixed combina-
tion of betahistine and nimodipine was associated with a significant reduction of tinnitus annoyance and improvement of hearing loss (p < 
0.005). it was concluded that nimodipine represents not only a valid add-therapy for ménière’s disease, and that it may also exert a specific 
effect on inner ear disorders. Further studies to investigate this possibility are needed.
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riASSunTo
Nonostante sia stata proposta una pletora di trattamenti farmacologici a lungo termine per ridurre la frequenza delle crisi di vertigine 
dovute alla malattia di Ménière, non esiste nella letteratura scientifica un consenso generale sulla loro efficacia. In questo studio retro-
spettivo vengono riportati i risultati di 10 anni di esperienza clinica relativa all’impiego di due protocolli farmacologici a lungo termine 
prescritti ai pazienti con diagnosi definitiva di malattia di Ménière (secondo i criteri dell’American Academy of Otolaryngology – Head 
and Neck Surgery Committee on Hearing and Equilibrium) che completarono il trattamento nel periodo 1999-2009. Sono state selezionate 
a questo scopo 113 cartelle cliniche; di queste, 53 relative a pazienti trattati con una somministrazione di betaistina-dicloridrato alla dose 
giornaliera di 32 mg per sei mesi mentre le altre 60 riguardavano pazienti trattati con una terapia addizionale di nimodipina alla dose 
giornaliera di 40 mg, per lo stesso periodo di tempo. La nimodipina, una 1,4 diidropiridina che blocca selettivamente i canali del calcio 
ad alto voltaggio di tipo L, era stata precedentemente testata come terapia monocomponente nelle vertigini ricorrenti di origine labirintica 
in uno studio multinazionale, in doppio-cieco riportando risultati positivi. Una moderata, seppure significativa, riduzione della percezione 
della disabilità relativa alla vertigine (valutata con l’impiego del Dizziness Handicap Inventory) è stata osservata nei pazienti trattati con 
betaistina (p < 0,05), ma un effetto maggiore è stato raggiunto nei pazienti trattati con l’associazione fissa dei due composti (p < 0,005). 
Con quest’ultima terapia, inoltre, si è ottenuto un controllo più efficace della vertigine (p < 0,005) in relazione alla frequenza degli attac-
chi. Entrambi i protocolli sono risultati in grado di migliorare significativamente il controllo posturale statico ma anche in questo caso un 
effetto più consistente è stato raggiunto dall’associazione dei due farmaci. La betaistina impiegata come monoterapia non ha avuto effetti 
significativi sul fastidio creato dal tinnito (valutato secondo il Tinnitus Handicap Inventory) nè tantomeno sulla perdita dell’udito (media 
aritmetica della soglia tonale per le frequenze di 0,5, 1, 2, 3 kHz nell’orecchio interessato) (p > 0,05). L’associazione di betaistina e nimo-
dipina, all’opposto, ha determinato tanto una significativa riduzione del fastidio relativo alla presenza del tinnito quanto un miglioramento 
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Introduction
Pharmacological treatment of acute episodes in ménière’s 
disease (mD) does not usually represent a clinical prob-
lem since vestibular suppressants, including antihista-
mines such as promethazine, anticholinergic antiemetics 
like dimenhydrinate, and diazepam are almost always ef-
fective in reducing the most unpleasant symptoms namely 
vertigo, nausea and vomiting in a very short time 1. Al-
ternatively, infusion of diuretics appears to be somewhat 
useful even if their routine use should be adopted with 
caution because of dose-dependent, adverse side effects 2. 
however, long-term pharmacological treatment aimed to 
reduce the frequency and intensity of vertigo attacks or 
even prevent flare-ups is a topic of general debate. First 
of all, even though it is generally accepted that mD is as-
sociated with endolymphatic hydrops (raised endolymph 
pressure in the membranous labyrinth of the inner ear), a 
definitive regimen for as long-term therapy remains elu-
sive because the underlying aetiology of this condition 
is still not fully understood. Secondly, as pointed out by 
Jongkees in 1980  3, mD spontaneously shows variably 
lengthy symptom-free periods, and therefore it is difficult 
to differentiate spontaneous remission from a therapeutic 
effect. Thirdly, studies adopted different designs, dura-
tion of treatment and drug dosages as well as methods to 
monitor outcomes so that results are rarely comparable. 
Finally, some studies included various peripheral vestibu-
lar diseases as cause of recurrent vertigo and results con-
cerning mD alone cannot be extracted 4 5.
nevertheless, some prevalent trends can be identified 
from the medical literature. For example, diuretics alone 
(acetazolamide) or in association with a low-salt diet are 
widely and routinely used, especially in the uSA  6 and 
uK 7, although a recent review stated that their efficacy has 
not been demonstrated in adequate randomised, placebo-
controlled studies 8. Similar conclusions about betahistine, 
a structural analogue of histamine, were reported in a meta-
analysis in 2001, revisited in 2011 9, in contrast to other re-
views which have concluded that its efficacy and safety are 
fully supported by modern evidence-based standards 10 11. 
There is also an increasing interest for the effect of betahis-
tine-dihydrochloride at dosages higher than those routinely 
used in the past (32 mg tid and lower), while the results 
of three recent open trials were controversial 12-14. Calcium 
channel blockers, namely flunarizine, cinnarizine and ni-
modipine in the treatment of vertigo have been used for 
many years in Europe 15, and their efficacy and safety have 
been investigated in two double-blind studies that included 
different types of recurrent vestibular vertigo 16 17. only two 
pilot studies specifically investigated the beneficial use of 
nimodipine in the medical treatment of mD 18 19, and both 
reported encouraging results. interestingly, there are few 
clinical trials about the use of combination of drugs in the 
treatment of mD 20 despite experimental evidence suggest-
ing that multi-component therapeutics often are more suc-
cessful than single component treatment 21. 
Therefore, the aim of this work was to retrospectively ana-
lyze the results of 16 mg of betahistine-dihydrochloride 
taken twice a day (32 mg die) for six months as a single 
component therapy versus a fixed combination of 16 mg of 
betahistine-dihydrochloride taken twice a day (32 mg die) 
and 20 mg of nimodipine taken twice a day (40 mg die) 
for 6 months in patients with mD in the period from 1999-
2009. The former long-term pharmacological treatment 
was the medical management of patients with definite mD, 
according to the American Academy of otolaryngology-
head and neck Surgery (AAo-hnS) Committee on hear-
ing and Equilibrium diagnostic guidelines (Appendix 1) 22, 
prescribed by the first author from 1999 to 2003. Thereaf-
ter, the latter therapeutic protocol was used and is still em-
ployed with minor adjustments before adopting intratym-
panic gentamicin injection and/or ablative procedures if 
systemic pharmacological treatment results unsatisfactory.
Materials and methods
Selection of medical records
of 6251 outpatients who attended the tertiary Centre for 
Vestibular Diseases and rehabilitation of the university 
hospital of modena, italy, in the period 1999-2009, 258 
were diagnosed with definite mD. Criteria for medical 
records to be included were established in a preliminary 
session by three senior audiologists (m.D, g.E, P.l.). 
Cases to be included in the study were relative to patients 
affected by: (a) unilateral mD, diagnosed as definite; (b) 
functional level between 1 and 5; c) all mD patients should 
have completed medical treatments with no or minor ad-
verse effects; d) all selected medical charts should include 
a complete history of patient, neurological and otologi-
dell’ipoacusia (p < 0,005). Pertanto è stato possibile concludere che la nimodipina rappresenta non solo una valida terapia aggiuntiva 
rispetto alla singola betaistina nel trattamento farmacologico a lungo termine della malattia di Ménière, ma che potrebbe di per sé eser-
citare un effetto positivo su diverse disfunzioni dell’orecchio interno, in particolare dell’organo del Corti. Ulteriori studi per approfondire 
tale ipotesi risultano comunque necessari.
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cal examinations. Pure-tone audiometry, tympanometry, 
electronystagmography (including caloric tests), pos-
turography and self-assessment questionnaires should be 
available at admittance and at the end of follow-up. Charts 
were completed by at least one magnetic resonance imag-
ing to exclude the Viii nerve and cerebellar and brainstem 
lesions. Exclusion criteria were (a) previous or current 
professional exposure to noise and noise-induced hearing 
loss; (b) middle ear diseases; (c) previous ablative surgery 
procedures; (d) previous intratympanic gentamicin and/
or corticosteroids injections; (e) other simultaneous treat-
ments namely diuretics, corticosteroids, vasodilators and 
low-salt diet; (f) bilateral mD because other treatment 
modalities, including corticosteroids, were adopted; (g) 
functional level scale > 5 because of gentamicin intratym-
panic injection and/or vestibular neurectomy were direct-
ly prescribed to patients in such cases. Four younger co-
workers (Bmr, ACm, ACE and nV) who were blinded 
to the purpose of the study selected 113 medical records 
that met inclusion criteria. in 53 cases, mD patients had 
been treated with betahistine (group A), and in 60 cases 
with the fixed combination of betahistine and nimodipine 
(group B). This study was approved by the Ethical Com-
mittee of the university hospital of modena in 2010 (ref. 
102/6-010).
Efficacy outcome parameters
According to the AAo-hnS Committee on hearing and 
Equilibrium guidelines for evaluation of therapy (ap-
pendix 1) control of vertigo was assessed by the formula 
(X/y) x 100, where X is the average number of definitive 
spells per month for 6 months (from 18 to 24 months after 
therapy), and y is the average number of definitive spells 
per months for the 6 months before therapy. The greater 
the number, the less efficacious the effect of treatment 
on the frequency of spells. These data were collected by 
routinely inviting mD patients to report their symptoma-
tology in a standardized diary card. Furthermore, hearing 
function changes were assessed by comparison between 
the worst audiogram (four-tone average hearing threshold 
at 0.5, 1, 2 and 3 khz in the affected ear) of each of the 
same two six-month intervals. Finally, stage of disease 
and functional levels were also determined in the afore-
mentioned time intervals. These latter data were recorded 
during periodic check-up visits. These outcome param-
eters were chosen to follow the AAo-hnS Committee on 
hearing and Equilibrium main guidelines for evaluation 
of therapies and allows comparison of the results of this 
study with those of other international experiences 23.
Further outcome measures
in accordance to the standardized diagnostic protocol of 
the Centre for Vestibular Disease and rehabilitation of the 
university hospital of modena, the total scores of two 
self-administrated psychometric questionnaires regard-
ing perceived dizziness disability (Dizziness handicap 
inventory) 24 and tinnitus annoyance (Tinnitus handicap 
inventory) 25 before therapy and at the end of follow-up 
were also considered. The Dizziness handicap inven-
tory is a 25-item questionnaire internationally adopted 
to appreciate the multidimensional impact of vertigo on 
self-perceived disability. A “yes” response gives a score 
of 4 points, “sometimes” 2 points, and “no” 0 points. 
The total score ranges from zero (no disability) to 100 
(severe disability). The Tinnitus handicap inventory is a 
25-item questionnaire designed to assess the severity of 
tinnitus annoyance. Each item has 3 potential answers 
with “yes” assigned 4 points, “sometimes” 2 points, and 
“no” 0 points. This leads to a total score ranging from 0 
indicating no tinnitus handicap and 100 the worst annoy-
ance. The italian versions of both Dhi and Thi have been 
demonstrated to maintain the same validity as the original 
ones 26 27. Posturographic data were also taken into con-
sideration, and were obtained using a stable force-plate 
sensitive to vertical forces (S.Ve.P, Amplifon). Patients 
were requested to maintain a relaxed, motionless upright 
stance, stand bare foot with feet at an angle of 30°, with 
a natural head-neck posture, under 4 different conditions: 
1) gazing at a steady, vertical light bar at a distance of 
150 cm (Eo), 2) with eyes closed in total darkness (EC), 
3-4) facing the wall in front on which a digital projec-
tor offered a full-field linear optokinetic stimulation rep-
resented by vertical alternating dark and light stripes 30 
cm in diameter, delivered at a speed of 30°/sec, in the 
horizontal plane. The optokinetic visual stimulation was 
firstly delivered toward the normal labyrinth (oKS-nl) 
and then towards the affected one (oKS-Al). These two 
trails were specifically designed to test postural reaction 
to visual-vestibular conflicting environmental conditions, 
which are known to be critical for patients with an un-
compensated vestibular lesion 28 29. The duration of each 
test was 52.2 sec and the analysis frequency of signal was 
5 hz. The body sway path was computed by detecting the 
body’s centre of pressure and calculating an elliptic area, 
which corresponds to 90% of its position over time and 
expressed in mm. This procedure was designed to elimi-
nate 10% of the more extreme positions that could be due 
to involuntary perturbations of quiet stance.
Statistical analyses
As a preliminary statistical analysis, the Student’s inde-
pendent t-test was used to compare the age of patients 
before treatment. A chi-square (χ2) procedure was per-
formed to test the null hypothesis that mD patients were 
not differently distributed in the two selected samples 
before treatment with respect to gender, stage of disease, 
functional level and presence of tinnitus. The same sta-
tistical procedure was adopted to analyze the distribution 
of patients with respect to functional level and stage of 
disease at the end of follow-up. Finally, the χ2 procedure 
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was employed to verify the null hypothesis that the distri-
bution of mD patients who reported unsatisfactory con-
trol of vertigo, and were hence submitted to intratympanic 
gentamicin injections was not different in the two sam-
ples. The paired T-test was performed to compare PTA 
of the affected ear (the worst audiogram available before 
admittance to therapy and in the follow-up period after 
treatment), Dhi and Thi scores, body sway path in Eo, 
EC, oKS-nl and oKS-Al before treatment and at the 
end of follow-up. independent-T test was again adopted 
to compare control of vertigo in the two groups. The SPSS 
package (version 16.0 SPSS inc., Chicago, illinois, uS) 
Table I. Distribution of patients with definite MD in Group A and B considering gender, stage of disease and functional level before medical treatment. Pear-
son’s chi-square values, df and asymptotic significance are reported (percentages in brackets).
Group A (n = 53) Group B (n = 60) χ2
Gender Males Females Males Females Value df Asympt Sig.
21 (40) 32 (60) 19 (32) 41 (68) 0.799 1 0.246
Stage 2 3 4 2 3 4
8 (15) 37 (70) 8 (15) 3 (5) 46 (77) 11 (18) 3.301 2 0.192
Functional Level 3 4 5 3 4 5
8 (15) 42 (79) 3 (6) 4 (7) 50 (83) 6 (10) 2.605 2 0.272
* Asymptotic significance p < 0.05; † asymptotic significance p < 0.005.
Table II. Distribution of patients with definite MD considering stage of disease and functional level after follow-up. Pearson’s chi-square values, df and as-
ymptotic significance are reported (percentages in brackets).
Stage Group A (n = 53) Group B (n = 60) χ2         
Value df Asympt Sig.
1 2 3 4 1 2 3 4
3 (6) 14 (26) 19 (36) 17 (32) 6 (10) 19 (32) 29 (48) 6 (10) 8.7 3 0.034*
Functional Level
1 2 3 4 5 1 2 3 4 5
4 (8) 16 (30) 7 (13) 22 (41) 4 (8) 6 (10) 36 (61) 11 (18) 5 (8) 2 (3) 19.9 4 0.001†
* Asymptotic significance p < 0.05; † asymptotic significance p < 0.005.
Table III. Mean values and standard deviations of PTA, THI and DHI scores before therapy and at the end of follow-up in Groups A (treatment = betahistine) 
and B (treatment: betahistine and nimodipine) and paired t-test values.
Group A Before therapy After therapy Paired T-test
Mean SD Mean SD t df p
PTA (affected ear) 54.1 12.6 52.3 19.6 1.03 52 0.307
DHI (total score) 50.1 11.7 46.4 13.7 2.6 52 0.012*
THI (total score) 28.5 23.4 28.9 21.8 -0.26 52 0.796
Group B
PTA (affected ear) 56.4 10.5 47.3 16.8 4.9 59 < 0.001†
DHI (total score) 52.3 11.4 44.8 17.5 3.5 59 < 0.001†
THI (total score) 27.8 14.7 23.7 12.0 4.2 59 < 0.001†
* p < 0.05; † p < 0.005.
Table IV. Mean values, standard deviations and paired t-tests of body sway path in eye open (EO), eye closed (EC), during full-field horizontal stimulation 
towards the affected ear (OKS-AL) and to the normal one (OKS-NL)before therapy and at the end of follow-up in Groups A (treatment = betahistine) and B 
(treatment = betahistine and nimodipine).
Group A Before therapy After therapy Paired T-test
Sway path Mean SD Mean SD t df p
EO 358.8 274.5 321.6 335.2 0.6 52 0.547
EC 575.4 261.1 458.0 202.9 2.4 52 0.023*
OKS-AL 483.9 296.9 442.1 281.9 2.5 52 0.014*
OKS-NL 373.3 293.8 320.9 157.4 1.4 52 0.151
Group B
EO 320.8 303.6 167.2 128.4 3.5 59 0.001†
EC 494.1 207.6 368.6 146.8 3.5 59 0.001†
OKS-AL 443.7 335.5 317.6 121.0 3.3 59 0.002†
OKS-NL 327.7 291.8 186.4 137.1 2.4 59 0.006*
* p < 0.05; † p < 0.005.
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was used, and statistical significance level was set at p < 
0.05 in all procedures.
Results
mean age did not differ significantly between patients in 
group A (mean = 45.3, SD = 6.7) and B (mean = 43.9 SD 
= 7.3) (t = 1.04, df = 111, p = 0.299). Patients with mD 
were not differently distributed in the two groups consid-
ering gender (χ2 > 0.05), stage of disease (χ2 > 0.05) and 
functional level before therapy (χ2 > 0.05) (Table i). Tin-
nitus was present in 46 patients in group A (87%) and in 
47 patients in group B (78%) (Pearson’s value = 1.4, df 
= 1, χ2 = 0.240). it could be noted that no mD patients 
with stage 1 and/or functional level below 3 were present; 
one explanation is that both possible and probable mD 
were not included, and that patients with initial and mild 
symptomatology are not usually referred to the tertiary 
Centre for Vestibular Diseases and rehabilitation. An-
other explanation is that only patients with definite mD 
were enrolled in this retrospective analysis and probably 
which led to the exclusion of patients with uncertain di-
agnosis and/or mild hearing and vestibular dysfunctions. 
As seen in Table ii, significant changes in the distribution 
of mD patients of the two groups were seen in the follow-
up period. in particular, the percentages of mD patients 
in group B belonging to the 1th, 2nd and 3th stages were 
higher than those in group A and lower for the 4th and 5th 
stages (χ2 < 0.05). moreover, PTA in patients in group A 
did not show any significant improvement in the interval 
between the 6 months before treatment and the 6 months 
of follow-up after one year from the end of therapy (p 
> 0.05) (Table iii). in contrast, a significant amelioration 
of PTA in group B was observed in the follow-up pe-
riod compared to the period before treatment (p < 0.005) 
(Table iii). Taken together, these results suggest a better 
therapeutic effect of the fixed combination of betahistine 
and nimodipine on hearing acuity than betahistine alone.
At follow-up, the percentages of patients in group B were 
significantly higher than those in group A considering the 
functional levels from 1 to 3 and lower for the 4th and 5th (χ2 
< 0.005), thus suggesting a greater beneficial effect of the 
fixed combination of compounds on the impact of vertigo 
on daily activities (Table iii). This result is corroborated 
by the observation that mD patients treated with the fixed 
association of betahistine and nimodipine showed a better 
control of vertigo at the end of the follow-up (mean =13.3, 
SD = 25.3) than mD patients who were treated with be-
tahistine alone (30.7, SD = 30.8) (independent t-test: t = 
3.3, df =111, p = 0.001) (Fig. 1). it should be observed that 
large values of standard deviation for both groups clearly 
suggest a great inter-individual variability to both thera-
peutic modalities. mD patients in group A did not report 
any decrease in tinnitus annoyance between admittance 
to therapy and the end of follow-up (p > 0.05) (Table iii). 
however, the perception of dizziness handicap as assessed 
by Dhi was moderately reduced in the same interval (p < 
0.05) (Table iii). A highly significant reduction of tinnitus 
annoyance (p < 0.005) as measured by the Thi score in the 
interval between admittance to therapy (mean = 27.8) and 
the end of follow-up (mean = 23.7) was observed in mD 
patients of group B (Table iii). These patients also reported 
a more significant reduction (p < 0.005) of perceived dizzi-
ness handicap as expressed by Dhi score at the end of fol-
low-up compared to the period before treatment than those 
in group A (Table iii). As seen in Table iV, the total amount 
of body sway path of group A patients in Eo and oKS-nl 
conditions did not significantly vary (p > 0.05); however, a 
moderate but significant decrease of body sway path was 
present at the end of follow-up in EC and oKS-Al condi-
tions (p < 0.05). more remarkable reductions of body sway 
area were recorded in group B; body sway path was greatly 
reduced in Eo, EC and oKS-Al conditions (p < 0.005) 
and a moderate but significant decrease was observed in 
oKS-nl condition (p < 0.05) (Table iV). Since 13 patients 
in group A (24.5%) and 4 (6.7%) in group B continued 
to experience frequent relapses of vertigo after the end of 
follow-up, a total of 17 patients (15%) were submitted to 
intratympanic gentamicin instillation. The distribution of 
these patients with unsuccessful medical results was not 
similar in the two groups; the number of mD patients in 
group A that underwent intratympanic gentamicin injection 
was significantly greater than that in group B (Pearson’s 
χ2  = 7.1, df = 1, asymptotic significance = 0.008).
Discussion
Betahistine, a structural analogue of histamine with weak 
histamine h(1) receptor agonist and more potent h(3) 
receptor antagonist properties, has been demonstrated 
to improve vestibular compensation in animal mod-
Fig. 1. Effect of betahistine-dihydrochloride at an on-label dosage of 32 
mg/bid (Group A) vs a fixed combination of betahistine-dihydrochloride at the 
same dosage and nimodipine (40 mg/bid) as an add-on, off-label therapy 
(Group B) on control of vertigo in 113 MD patients (* = p < 0.005).
*
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els of unilateral failure of vestibular function by dif-
ferent mechanisms  30. in the central nervous system, 
it improves histamine synthesis within the posterior 
hypothalamus and enhances histamine release within 
vestibular nuclei through antagonism of h(3) heter-
oreceptors. The action of histamine on the vestibular 
nuclear cells on the affected side is considered the key 
mechanism that produces a rebalancing of neuronal 
activity between the two sides to promote recovery. 
in the inner ear of guinea pigs, betahistine increases 
blood flow by antagonizing local h(3) receptors re-
sulting in an increased blood flow both in the posterior 
semicircular canal ampulla  31 and cochlear vessels  32. 
A better perfusion of the inner ear vasculature has been 
presumed to be the basic mechanism by which beta-
histhine can potentially ameliorate inner ear vascular 
disorders that animal investigations have suggested to 
occur in the chronic hydropic ear 33. moreover, the peri-
lymphatic administration of betahistine could greatly 
reduce the resting discharge of the ampullar receptor in 
the frog semicircular canal, postulating its possible in-
hibitory effects on the abnormal activity of the sensory 
hair cells induced by hydrops  34. moreover, in humans 
betahistine hydrochloride acts as a potent cerebral and 
peripheral microcirculatory vasodilator both in normal 
subjects  35 and in patients affected by cerebrovascular 
disease  36 when given orally. it is also known to facili-
tate vestibular compensation in patients with disabling 
mD after vestibular neurectomy by rapidly reducing the 
asymmetry of the vestibulo-ocular reflex (Vor) 37. Disap-
pointingly, experimental results of drugs on Vor are ex-
tremely rare in humans 38; nonetheless, it has been clearly 
demonstrated that betahistine can differently affect Vor 
dynamics, namely velocity gain and duration of nystag-
mus, depending on the frequency of stimulation that is 
probably due to a specific activity on neurotransmission 
within the vestibular nuclei 39. The possibility that beta-
histine can act as a neurotransmitter or a neuromodula-
tor at peripheral vestibular end organs in humans is more 
controversial primarily because it has been observed that 
astemizole, an h(1) receptor antagonist that does not pen-
etrate the blood-brain barrier, suppresses nystagmus in 
patients with chronic dizziness 40. From this point of view, 
it seems a contradiction to treat patients with a structural 
analogue of histamine for a symptom that is also relieved 
by systemic antihistamines 41.
nevertheless, the results of this study corroborate the 
most recent advances regarding the efficacy of betahis-
tine in the long-term medical treatment of mD as on-label 
administration (32 mg die). in fact, it has been confirmed 
that it reduces the frequency of vertigo attacks  12  13 and 
improves quality of life through a significant reduction of 
perceived dizziness handicap in mD patients as well as in 
patients with various types of recurrent vertigo 5 42. This 
study also focused on the efficacy of betahistine on the 
asymmetry of vestibulo-spinal reflexes, which appears to 
be one of the less frequently investigated aspect of mD; 
stabilometric data has shown that postural control is mod-
erately improved by this treatment both in visual depriva-
tion and in visual-vestibular mismatch conditions. There-
fore, it supports a previous observation about its efficacy 
in the reduction of vestibulo-spinal reflex impairment and 
unsteadiness that occur in mD patients after vestibular 
neurectomy 43.
it is also been suggested that tinnitus annoyance and hear-
ing loss due to mD are far less amenable to treatment with 
betahistine 9 44 45 since both Thi total score and pure tone 
hearing threshold did not significantly improve.
nimodipine, a 1,4 dihydropyridine that selectively blocks 
l-type voltage-sensitive calcium channels, is now consid-
ered to be a safe and well-documented drug for reduc-
tion of the severity of neurologic deficits resulting from 
vasospasm in subarachnoid haemorrhage 46. The mecha-
nism of nimodipine beneficial effect in such patients is not 
completely elucidated. it has both a preferential cerebral 
vasodilator action and a direct effect involving prevention 
of calcium overload in neurons, responsible of cellular 
damages, by a blocking action on l-type voltage-sensitive 
calcium channels. Administration of nimodipine induces 
an increase in plasma adenosine levels, a well-known va-
sodilatatory compound with a short biological half-life 
on brain circulation in humans 47. There is also evidence 
that nimodipine may have a neuroprotective effect against 
ischaemia by entering into the cell and inhibiting exces-
sive calcium ion influx in the mitochondria 48. increased 
fibrinolytic activity has been observed in patients with 
aneurysmal subarachnoid haemorrhage following treat-
ment with nimodipine. This is considered to be due to a 
nimodipine-induced decrease in the level of plasminogen 
activator inhibitor 49 50. This data suggests that nimodipine 
may act as an analogue of tissue-type plasminogen ac-
tivator whose role is well-established in the treatment 
of sudden and chronic sensorineural hearing loss 51. The 
off-label use of nimodipine in the treatment of peripheral 
vestibular disorders is supported by several lines of ex-
perimental data, and for example, there is good evidence 
for calcium channels at the periphery of the vestibular 
system that are predominantly the l-type 52. The effect of 
several calcium channel agonists and antagonists on the 
whole nerve firing rate in an isolated frog semicircular 
canal preparation have been studied  53. Even if resting 
activity was affected by all dihydropyridines tested, only 
nimodipine was able to reduce the mechanically-evoked 
activity. This suggests that nimodipine might potentially 
reduce spontaneous nystagmus due to an abnormal resting 
discharge of vestibular hair cells induced by an increased 
pressure of the endolymph 54.
in brainstem, neurons in the medial vestibular nucleus 
show adaptive changes in firing rate responses that are 
correlated with Vor gain (the ratio of evoked eye ve-
nimodipine and betahistine in the long-term treatment of ménière’s disease
399
locity to input head velocity). moreover, neurons of the 
vestibular medial nuclei express l, T and n-type calcium 
channels  55. Thus, calcium-channel blockers can differ-
ently affect Vor depending on the functional role of the 
subtypes of channel in each synapse. in fact, the firing 
rate response of neurons in the medial vestibular nuclei 
is reduced by increasing extracellular calcium and in-
creased either by lowering extracellular calcium or with 
antagonists to calcium-dependent potassium channels and 
n- and T-type calcium channels  56. When tested in eld-
erly patients with chronic cerebrovascular disorders, ni-
modipine appears to enhance learning and memory 57 that 
are cognitive functions whose role is crucial during ves-
tibular compensation process 58. Finally, since nimodipine 
has been used as prophylaxis for migraine, it is possible 
that it also exerts a beneficial effect on the course of mD 
as for other antimigrainous drugs 59 even if the underlying 
mechanism remains to be elucidated.
l-type calcium channels have been described in the pe-
ripheral auditory systems of different species, and it has 
been shown that they primarily mediate neurotransmitter 
release from hair cells 60. Diffusion of nimodipine into 
the scala tympani of the cochlea significantly elevated 
threshold, decreased the amplitude and increased the la-
tency of the action potential in a reversible manner  61. 
moreover, it has been shown that the mobility of the 
outer hair cells in the organ of Corti is inhibited by the 
presence of nimodipine suggesting its protective role 
compared to their abnormal mechanical stimulation due 
to the hydropic pressure on the cochlear structures  62. 
in fact, the results of this study clearly demonstrate the 
beneficial effect of nimodipine as an add-on therapy in 
definite mD because its fixed combination with betahis-
tine resulted in a more efficient control of vertigo spells, 
greater amelioration of perceived dizziness handicap and 
better control of static posture in all visual conditions 
than betahistine as a single component therapy. Despite 
these observations, which clearly indicate an additional 
beneficial effect of nimodipine in the treatment of mD, 
no conclusion about its own interaction with the vestibu-
lar system in humans is actually definitive. nimodipine 
appears to exert a specific effect on the auditory system 
since its use was associated with reduction of tinnitus an-
noyance and improvement of pure-tone hearing thresh-
old. These data partially confirm previous experimental 
evidence in an animal behavioural model 63 and clinical 
experience in humans 64. it therefore seems reasonable to 
accept the beneficial action of nimodipine on cochlear 
dysfunction on the basis of its well-documented effect 
on hair cell calcium channels whose dysfunction could 
play a dominant role in those inner ear disorders that can 
be referred to as “channelopathy 65. These results have 
at least two clinical implications; firstly, the question 
if the off-label prescription of nimodipine alone could 
be effective in mD, and secondly if its use should be 
extended to other types of inner ear dysfunctions and 
central vestibular disorders. Finally, it should be noted 
that no single or multicomponent medical treatment is 
associated to optimal control of vertigo in all patients 
with definite mD, so that intratympanic gentamycin in-
jection or ablative procedures are adopted in cases that 
are refractory to long-term medical treatments.
Conclusions
Betahistine has been prescribed to patients with mD 
for many years in Europe, and recent reviews suggest 
that it is both effective and safe in adequate double-
blind, controlled studies. As also suggested by this 
retrospective study, its efficacy is limited to control of 
vertigo spells. Disappointingly, no therapeutic effect 
of betahistine on tinnitus and hearing loss due to mD 
emerges from either the international medical literature 
or the results of this study. nonetheless, this retrospec-
tive study confirms recent clinical experience about its 
efficacy in reduction of postural symptoms due to the 
asymmetry of vestibulo-spinal reflexes. nimodipine 
exerts not only an additional effect on the control of 
vertigo attacks and a further reduction of vestibulo-spi-
nal impairment, but also a specific and positive action 
on tinnitus annoyance and sensorineural hearing loss. 
Therefore, the fixed combination of betahistine and ni-
modipine seems to provide patients with mD the typi-
cal advantage of a multicomponent therapy, namely a 
better control extended to the majority of symptoms. 
Further investigations with adequate study design on 
the off-label prescription of nimodipine alone in inner 
ear dysfunctions in humans are recommended.
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Appendix 1
American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) Committee 
on Hearing and Equilibrium diagnostic guidelines (1995)
Source
Department of Otolaryngology, University Health Network, University of Toronto, Ontario, Canada. thorp@nf.sympatico.ca
Diagnosis of Meniere’s Disease
Possible Meniere’s disease
• Episodic vertigo of the Meniere’s type without documented hearing loss, or sensorineural hearing loss, fluctuating 
or fixed, with dysequilibrium but without definitive episodes
• Other causes excluded
Probable Meniere’s disease
• One definitive episode of vertigo
• Audiometrically documented hearing loss on at least one occasion
• Tinnitus or aural fullness in the treated ear
• Other causes excluded
Definite Meniere’s disease
• Two or more definitive spontaneous episodes of vertigo 20 min or longer
• Audiometrically documented hearing loss on at least one occasion
• Tinnitus or aural fullness in the affected ear
• Other cases excluded
Certain Meniere’s disease
• Definite Meniere’s disease, plus histopathologic confirmation
Stage of disease
Staging of meniere’s disease proposed by AAo-hnS (1995) is based on the arithmetic mean of the pure tone thresholds 
at 0.5, 1, 2, and 3 khz of the affected ear, using the worst audiogram during the interval 6 months before treatment. Ac-
cordingly, stage i means four-tone average less than 26 dB; stage ii, 26-40 dB, stage iii, 41-70 dB, and stage iV, more 
than 70 dB
Stage Four-tones average (0.5, 1, 2, 3 kHz) (dB) 
1 < 26
2 26-40
3 41-70
4 > 70
Functional level scale (FLS)
According to AAo-hnS (1995) regarding the current state of overall function, not just functioning during attacks.
FLS Patient’s subjective experience
1 my dizziness has no effects on my activities at all
2 When i am dizzy, i have to stop what i am doing for a while, but it soon passes and i can resume 
activities. i continue to work, drive and engage in any activity i choose without restriction. i have 
not changed any plans or activities to accommodate my dizziness.
3 When i am dizzy, i have to stop what i am doing for a while, but it does pass and i can resume 
activities. i continue to work, drive and engage in most activities i choose, but i have had to 
change some plans and make some allowance for my dizziness 
4 i am able to work, drive, travel, take care of a family, or engage in most essential activities, but 
i must exert a great deal of effort to do so. i must constantly make adjustments in my activities 
and budget my energies. i am barely making it.
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5 i am unable to work, drive, or take care of my family. i am unable to do most of the active things 
that i used to do. Even essential activities must be limited. i am disabled.
6 i have been disabled for one year or longer and/or i receive compensation (money) because of 
my dizziness or balance problem
Control of vertigo
Stated that the frequency of definitive attacks of vertigo for the period six months before treatment should be compared 
with the frequency of attacks occurring in the interval 18 to 24 months after treatment and the formula to be applied 
is (X/y) x 100 rounded to the nearest whole number. X is the average number of definitive spells per months for the 
6 months 18 to 24 months after treatment and y the average number of crisis per month for the 6 months before. The 
greater the numerical expression, the worse the control of vertigo attacks after therapy.
Control 
of vertigo 
 Numerical value 
A 0 (complete control)
B 1-40
C 41-80
D 81-120
E > 120
F Secondary treatment initiated due to disability of vertigo
